Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BriaCell Therapeutics Corp (BCTXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: BCTXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -85.19% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.08M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.72 | 52 Weeks Range 0.02 - 0.70 | Updated Date 06/18/2025 |
52 Weeks Range 0.02 - 0.70 | Updated Date 06/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -131.54% | Return on Equity (TTM) -688.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5776754 |
Shares Outstanding - | Shares Floating 5776754 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
BriaCell Therapeutics Corp
Company Overview
History and Background
BriaCell Therapeutics Corp. is a biotechnology company focused on developing targeted immunotherapies for cancer. Founded with the goal of harnessing the power of the immune system to fight cancer, BriaCell has focused on novel approaches to stimulate the immune system to recognize and eliminate cancer cells. While specific founding year information isn't publicly and widely available, the company has been active in clinical trials and research for several years.
Core Business Areas
- Oncology Immunotherapy: Development of immunotherapies for advanced solid tumors, specifically focused on stimulating the immune system to target and eliminate cancer cells.
- Bria-IMTu2122 Platform: The company's main immunotherapy platform technology.
Leadership and Structure
BriaCell's leadership team consists of experienced professionals in the fields of oncology, immunology, and drug development. Specific details on the organizational structure may vary and are subject to change, reflecting the needs of a growing biotechnology company.
Top Products and Market Share
Key Offerings
- Bria-IMTu2122: Bria-IMTu2122 is BriaCell's lead investigational product, a targeted immunotherapy for advanced breast cancer. The therapy works by stimulating the patient's immune system to recognize and kill cancer cells. Since BriaCell is still in the clinical trial stage, it currently has no revenues. Competitors include major pharmaceutical companies like Roche (RHHBY), Merck (MRK), and Bristol-Myers Squibb (BMY) that have approved immunotherapies.
Market Dynamics
Industry Overview
The oncology immunotherapy market is experiencing substantial growth, driven by advancements in understanding the immune system's role in fighting cancer. The area is highly competitive and research-intensive with multiple players focusing on different types of immunotherapies.
Positioning
BriaCell focuses on a specific niche within the immunotherapy market, aiming to develop targeted immunotherapies for advanced cancers. Their competitive advantage lies in their unique approach to stimulate a broad and effective immune response against cancer cells.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach hundreds of billions of dollars in the coming years. BriaCell is positioned to potentially capture a portion of this market with successful clinical trial results and regulatory approvals for its Bria-IMTu2122 platform.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy platform (Bria-IMTu2122)
- Targeted approach for advanced cancers
- Experienced management team focused on oncology and immunology
Weaknesses
- Limited financial resources compared to major pharmaceutical companies
- Product is still in the clinical trial phase
- Reliance on successful clinical trial outcomes
Opportunities
- Positive clinical trial data leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion of Bria-IMTu2122 platform to other cancer types
- Increased funding through grants or investments
Threats
- Failure to achieve positive clinical trial results
- Competition from established immunotherapies
- Regulatory hurdles and delays
- Changes in the healthcare reimbursement landscape
Competitors and Market Share
Key Competitors
- MRK
- BMY
- RHHBY
Competitive Landscape
BriaCell faces intense competition from established pharmaceutical companies with extensive resources and approved immunotherapies. Its advantage lies in its unique approach, while its disadvantage stems from limited resources and the need to prove clinical efficacy.
Growth Trajectory and Initiatives
Historical Growth: BriaCell's growth has been marked by the progress of its Bria-IMTu2122 platform through clinical trials.
Future Projections: Future growth depends heavily on the success of ongoing and planned clinical trials. Analyst projections, if available, are based on the potential market opportunity and probability of success for Bria-IMTu2122.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Bria-IMTu2122, expansion of the research team, and efforts to secure additional funding.
Summary
BriaCell Therapeutics is a high-risk, high-reward biotech company focused on cancer immunotherapy. The company's future hinges on the successful development and commercialization of its Bria-IMTu2122 platform. While its novel approach presents an opportunity, it faces significant challenges from larger, well-established competitors and the inherent uncertainties of clinical trials. BriaCell needs to secure adequate funding and demonstrate positive clinical data to realize its potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- ClinicalTrials.gov
- Various financial news sources
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market conditions are subject to change. Investing in biotechnology companies involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BriaCell Therapeutics Corp
Exchange NASDAQ | Headquaters West Vancouver, BC, Canada | ||
IPO Launch date 2021-02-24 | CEO, President & Director Dr. William V. Williams FCPA, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://briacell.com |
Full time employees - | Website https://briacell.com | ||
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.